Hill Robert, Travis Simon, Ardalan Zaid
Translational Gastroenterology Unit, University of Oxford, Oxford, United Kingdom.
Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom.
Gastroenterol Hepatol (N Y). 2025 Jan;21(1):46-58.
Chronic pouchitis affects 13% to 17% of patients with ileal pouch-anal anastomosis and ulcerative colitis, and 20% with a history of acute pouchitis. It is classified by antibiotic responsiveness into chronic antibiotic-dependent pouchitis and chronic antibioticrefractory pouchitis. Pathogenesis of chronic pouchitis can range from microbially mediated to more antibiotic-resistant and immune-mediated processes. A diagnostic index combining clinical, endoscopic, and histologic components is essential for clinical practice and research. In chronic antibiotic-dependent pouchitis, remission is managed with microbiota- or immune-targeted therapies. For chronic antibiotic-refractory pouchitis, immune-directed therapy is primary, with vedolizumab recommended for first-line treatment. Other advanced therapies rely on less definitive evidence, and efficacy may be reduced by precolectomy exposure. This article reviews the pathogenesis, diagnosis, and management of chronic pouchitis.
慢性袋炎影响13%至17%的回肠袋肛管吻合术和溃疡性结肠炎患者,以及20%有急性袋炎病史的患者。根据对抗生素的反应性,可将其分为慢性抗生素依赖性袋炎和慢性抗生素难治性袋炎。慢性袋炎的发病机制范围从微生物介导到更具抗生素抗性和免疫介导的过程。结合临床、内镜和组织学成分的诊断指数对临床实践和研究至关重要。在慢性抗生素依赖性袋炎中,缓解通过微生物群或免疫靶向疗法进行管理。对于慢性抗生素难治性袋炎,免疫导向疗法是主要的,推荐维多珠单抗用于一线治疗。其他先进疗法依赖的证据不太确凿,且结肠切除术前的暴露可能会降低疗效。本文综述了慢性袋炎的发病机制、诊断和管理。